# Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension

> **NCT02178098** · PHASE2 · COMPLETED · sponsor: **Esperion Therapeutics, Inc.** · enrollment: 143 (actual)

## Conditions studied

- Hypercholesterolemia
- Hypertension

## Interventions

- **DRUG:** ETC-1002
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02178098
- **Lead sponsor:** Esperion Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-16
- **Primary completion:** 2015-05-22
- **Final completion:** 2015-05-22
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2023-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02178098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02178098, "Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02178098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*